HighMark Wealth Management LLC Decreases Holdings in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

HighMark Wealth Management LLC lowered its position in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) by 0.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 166,135 shares of the company’s stock after selling 1,000 shares during the period. Centessa Pharmaceuticals makes up about 1.6% of HighMark Wealth Management LLC’s investment portfolio, making the stock its 11th largest position. HighMark Wealth Management LLC owned approximately 0.13% of Centessa Pharmaceuticals worth $2,783,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in CNTA. Mirae Asset Global Investments Co. Ltd. boosted its stake in Centessa Pharmaceuticals by 47.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock valued at $40,000 after acquiring an additional 826 shares during the period. GAMMA Investing LLC grew its holdings in Centessa Pharmaceuticals by 29.1% during the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock worth $64,000 after acquiring an additional 865 shares during the period. Walleye Capital LLC bought a new stake in Centessa Pharmaceuticals in the third quarter worth about $187,000. China Universal Asset Management Co. Ltd. lifted its holdings in Centessa Pharmaceuticals by 99.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,593 shares of the company’s stock valued at $217,000 after acquiring an additional 6,785 shares during the last quarter. Finally, Atria Investments Inc boosted its position in shares of Centessa Pharmaceuticals by 7.0% during the 3rd quarter. Atria Investments Inc now owns 17,134 shares of the company’s stock valued at $274,000 after purchasing an additional 1,116 shares in the last quarter. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Insider Buying and Selling

In other Centessa Pharmaceuticals news, insider Gregory M. Weinhoff sold 10,000 shares of the company’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $17.66, for a total transaction of $176,600.00. Following the transaction, the insider now directly owns 183,266 shares in the company, valued at approximately $3,236,477.56. This represents a 5.17 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $16.89, for a total transaction of $928,950.00. Following the sale, the chief executive officer now owns 575,661 shares of the company’s stock, valued at approximately $9,722,914.29. This represents a 8.72 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 452,652 shares of company stock worth $7,800,532 in the last quarter. Insiders own 11.59% of the company’s stock.

Centessa Pharmaceuticals Trading Down 3.1 %

Shares of NASDAQ CNTA opened at $17.07 on Tuesday. Centessa Pharmaceuticals plc has a 1-year low of $7.75 and a 1-year high of $19.09. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. The company has a 50-day moving average of $16.75 and a two-hundred day moving average of $15.73. The company has a market cap of $2.25 billion, a PE ratio of -11.16 and a beta of 1.53.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the company. Guggenheim reissued a “buy” rating on shares of Centessa Pharmaceuticals in a research note on Monday, February 10th. TD Cowen initiated coverage on Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating for the company. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $25.83.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.